Is Design Therapeutics, Inc. (DSGN) a Buy, Sell, or Hold?
NASDAQ : DSGN
Design Therapeutics, Inc. — Analyst Ratings
$13.57 USD
$0.37 (2.8%)
- Volume
- 443.14K
- Average Volume
- 959.17K
- Market Capitalization
- $847.54M
- P/E Ratio
- -11.50
- Dividend Yield
- 0.00%
- Price Target
- $20.50
- Year High
- $17.25
- Year Low
- $3.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.86
Analyst Consensus Summary
Consensus Rating
Sell
7 Analysts
Rating Score
2/5
Recommendation Strength
Upside/Downside
-33.8%
vs Current Price
Price Target
$20.50
Average TargetPrice Target Range
Lowest Target
$20.00
-32.2% DOWNSIDE
Average Target
$20.50
Median Estimate
Highest Target
$21.00
-35.4% DOWNSIDEAnalyst Breakdown
Overall Consensus: Buy | Total Analysts: 7
| Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|
| 0 | 4 | 3 | 0 | 0 |
Analyst Ratings (Detailed)
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| Craig-Hallum | Adam Vogel | $15 | $8.94 | 2025-12-03 07:38 AM | 67.8% |
| Leerink Partners | Joseph Schwartz | $14 | $8.94 | 2025-12-03 06:11 AM | 56.6% |
| Piper Sandler | Yasmeen Rahimi | $12 | $3.65 | 2024-05-06 11:04 PM | 228.8% |
| RBC Capital | Leonid Timashev | $7 | $2.165 | 2023-08-15 11:32 AM | 223.3% |
| Piper Sandler | Yasmeen Rahimi | $42 | $12.69 | 2022-12-07 02:14 PM | 231.0% |
| Goldman Sachs | Madhu Kumar | $10 | $13.98 | 2022-01-18 07:00 PM | -28.5% |